Overall impact
C (56)

Commentary

Soliton is an average overall performer. With a 'C' rating of 56.2 for overall impact (55th percentile compared to all companies), Soliton ranks 68th out of 96 industry peers, behind Suvoda, Gainwell Technologies, Healthequity and 64 others, and ahead of Maximus, Progyny, Schrodinger and 25 others. On top material causes for Soliton's industry (Healthcare Software & Services), Soliton performs well in Technology Innovation (95.6 score) and Improved Mental Health (95.4) and performs poorly in Accountable Institutions (24.2 score), Sustainable Use of Natural Resources (38.7), Reduced Green House Gas Emissions (39.7) and 3 other causes where it received a 'D' or 'F' score.
Impact
Cause SOLY
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
13
Sector
Health Care
Industry
Health Care Providers & Services
Sub-industry
Health Care Services
SASB industry
Software & IT Services
Headquarters
Tx, United States
Share classes
SOLY
Description
Soliton, Inc., a medical device company, develops and commercializes products using a proprietary rapid acoustic pulse technology platform. The company offers products for the removal of tattoos. It also develops a product for cellulite reduction, fibrotic scar treatment, and other indications. The company was incorporated in 2012 and is based in Houston, Texas. As of December 16, 2021, Soliton, Inc. operates as a subsidiary of Allergan plc.
Material causes
Ethos considers the following causes material for Soliton, based on its industry sub-industry Health Care Services. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.